Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
4(31%)
Results Posted
75%(3 trials)
Terminated
3(23%)

Phase Distribution

Ph phase_1
4
31%
Ph phase_2
2
15%
Ph early_phase_1
2
15%
Ph not_applicable
1
8%

Phase Distribution

6

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
2(22.2%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

4

trials recruiting

Total Trials

13

all time

Status Distribution
Active(4)
Completed(4)
Terminated(3)
Other(2)

Detailed Status

Completed4
Terminated3
Recruiting2
unknown2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
4
Success Rate
57.1%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (22.2%)
Phase 14 (44.4%)
Phase 22 (22.2%)
N/A1 (11.1%)

Trials by Status

recruiting215%
unknown215%
completed431%
terminated323%
active_not_recruiting215%

Recent Activity

4 active trials
Showing 5 of 13
active_not_recruitingnot_applicable

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

NCT05911178
active_not_recruitingearly_phase_1

Quantitative Imaging of Brain Glymphatic Function in Humans

NCT04768101
recruiting

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

NCT07482072
recruitingphase_1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

NCT06999434
completed

11C-PIB PET Study in MESA at Columbia University

NCT03981380
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05911178Not Applicable

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Active Not Recruiting
NCT04768101Early Phase 1

Quantitative Imaging of Brain Glymphatic Function in Humans

Active Not Recruiting
NCT07482072

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

Recruiting
NCT06999434Phase 1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Recruiting
NCT03981380

11C-PIB PET Study in MESA at Columbia University

Completed
NCT03958630Phase 1

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

Terminated
NCT03757910Early Phase 1

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Terminated
NCT06141356

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

Unknown
NCT04505735

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

Terminated
NCT01826110Phase 1

PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers

Completed
NCT03555292Phase 2

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Unknown
NCT02120664Phase 1

Florbetapir Calibration to the Centiloid Scale

Completed
NCT00855868Phase 2

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Completed

All 13 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
13